Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance

dc.contributor.authorBoukas, Leandros
dc.contributor.authorBjörnsson, Hans Tómas
dc.contributor.authorHansen, Kasper D.
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T08:35:50Z
dc.date.available2025-11-20T08:35:50Z
dc.date.issued2020-09-03
dc.descriptionAcknowledgments Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R01GM121459. L.B. was partly supported by the Maryland Genetics, Epidemiology, and Medicine (MD-GEM) training program, funded by the Burroughs Wellcome Fund. H.T.B. received support from the Louma G. Foundation. Publisher Copyright: © 2020en
dc.description.abstractThe aggregation and joint analysis of large numbers of exome sequences has recently made it possible to derive estimates of intolerance to loss-of-function (LoF) variation for human genes. Here, we demonstrate strong and widespread coupling between genic LoF intolerance and promoter CpG density across the human genome. Genes downstream of the most CpG-rich promoters (top 10% CpG density) have a 67.2% probability of being highly LoF intolerant, using the LOEUF metric from gnomAD. This is in contrast to 7.4% of genes downstream of the most CpG-poor (bottom 10% CpG density) promoters. Combining promoter CpG density with exonic and promoter conservation explains 33.4% of the variation in LOEUF, and the contribution of CpG density exceeds the individual contributions of exonic and promoter conservation. We leverage this to train a simple and easily interpretable predictive model that outperforms other existing predictors and allows us to classify 1,760 genes—which are currently unascertained in gnomAD—as highly LoF intolerant or not. These predictions have the potential to aid in the interpretation of novel variants in the clinical setting. Moreover, our results reveal that high CpG density is not merely a generic feature of human promoters but is preferentially encountered at the promoters of the most selectively constrained genes, calling into question the prevailing view that CpG islands are not subject to selection.en
dc.description.versionPeer revieweden
dc.format.extent12
dc.format.extent2768748
dc.format.extent487-498
dc.identifier.citationBoukas, L, Björnsson, H T & Hansen, K D 2020, 'Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance', American Journal of Human Genetics, vol. 107, no. 3, pp. 487-498. https://doi.org/10.1016/j.ajhg.2020.07.014en
dc.identifier.doi10.1016/j.ajhg.2020.07.014
dc.identifier.issn0002-9297
dc.identifier.other43006903
dc.identifier.other825f7bd9-2a19-4a25-9fa7-79aa61e1eeeb
dc.identifier.other85089944873
dc.identifier.other32800095
dc.identifier.urihttps://hdl.handle.net/20.500.11815/6546
dc.language.isoen
dc.relation.ispartofseriesAmerican Journal of Human Genetics; 107(3)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85089944873en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectCpG densityen
dc.subjectCpG islandsen
dc.subjectdosage sensitivityen
dc.subjectepigeneticsen
dc.subjectGC contenten
dc.subjectgnomADen
dc.subjecthaploinsufficiencyen
dc.subjectloss-of-functionen
dc.subjectpromotersen
dc.subjectselectionen
dc.subjectGeneticsen
dc.subjectGenetics (clinical)en
dc.titlePromoter CpG Density Predicts Downstream Gene Loss-of-Function Intoleranceen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
s41467-024-52472-6.pdf
Stærð:
2.64 MB
Snið:
Adobe Portable Document Format

Undirflokkur